Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H28O2 |
Molecular Weight | 300.4351 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CCC4=CC(=O)C=C[C@]34C
InChI
InChIKey=XWALNWXLMVGSFR-HLXURNFRSA-N
InChI=1S/C20H28O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h6,9,12,15-17,22H,4-5,7-8,10-11H2,1-3H3/t15-,16+,17+,18+,19+,20+/m1/s1
DescriptionSources: https://www.steroidal.com/steroid-profiles/dianabol/Curator's Comment: description was created based on several sources, including:
Lenehan, P. (2003) "Anabolic steroids", p.101 Retrieved from https://books.google.ru/books?id=TOePv6WpruQC | https://www.healthydietadvisor.com/bodybuilding-supplements/dianabol-review/
Sources: https://www.steroidal.com/steroid-profiles/dianabol/
Curator's Comment: description was created based on several sources, including:
Lenehan, P. (2003) "Anabolic steroids", p.101 Retrieved from https://books.google.ru/books?id=TOePv6WpruQC | https://www.healthydietadvisor.com/bodybuilding-supplements/dianabol-review/
Metandienone is an orally active synthetic anabolic-androgenic steroid. In 1970, the FDA accepted that Metandienone (Dianabol) was “Probably Effective” in treating post-menopausal osteoporosis and pituitary-deficient dwarfism. Methandrostenolone is still produced today, but typically in nations with loose prescription drug regulations and by companies that still prefer to cater to an underground athletic market. Androgenic side effects are still common with this substance. This may include bouts of oily skin, acne, and body/facial hair growth. Anabolic/androgenic steroids may also aggravate male pattern hair loss.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3072 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9593936 |
|||
Target ID: CHEMBL3859 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9593936 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Dianabol Approved UseIt is indicated for the treatment of post-menopausal osteoporosis and pituitary-deficient dwarfism. |
|||
Primary | Dianabol Approved UseIt is indicated for the treatment of post-menopausal osteoporosis and pituitary-deficient dwarfism. |
Doses
Dose | Population | Adverse events |
---|---|---|
15 mg 1 times / day multiple, oral Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
healthy, 20-48 years n = 15 Health Status: healthy Age Group: 20-48 years Sex: M Population Size: 15 Sources: |
Disc. AE: Infertility... AEs leading to discontinuation/dose reduction: Infertility (15 patients) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Infertility | 15 patients Disc. AE |
15 mg 1 times / day multiple, oral Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Sources: |
healthy, 20-48 years n = 15 Health Status: healthy Age Group: 20-48 years Sex: M Population Size: 15 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma. | 1972 Dec 16 |
|
Hypoplastic anemia associated with metolazone. | 1979 Jul 13 |
|
Poststeroid balance disorder--a case report in a body builder. | 1999 Aug |
|
[Coronary thrombosis and ectasia of coronary arteries after long-term use of anabolic steroids]. | 2003 Apr |
|
[Severe nephrotic syndrome in a young man taking anabolic steroid and creatine long term]. | 2003 Dec 7 |
|
Chronic administration of anabolic steroids disrupts pubertal onset and estrous cyclicity in rats. | 2003 Feb |
|
Successful treatment of anabolic steroid-induced azoospermia with human chorionic gonadotropin and human menopausal gonadotropin. | 2003 Jun |
|
Glucuronidation of anabolic androgenic steroids by recombinant human UDP-glucuronosyltransferases. | 2003 Sep |
|
[Assessment of mutagenic danger of food products]. | 2004 |
|
[Acute myocardial infarction in a young man who had been using androgenic anabolic steroids]. | 2004 Jan 22 |
|
Mass spectrometric identification and characterization of a new long-term metabolite of metandienone in human urine. | 2006 |
|
Collision-induced dissociation pathways of anabolic steroids by electrospray ionization tandem mass spectrometry. | 2006 Apr |
|
Doping control for metandienone using hair analyzed by gas chromatography-tandem mass spectrometry. | 2006 May 19 |
|
Anabolic steroid abuse among teenage girls: an illusory problem? | 2007 May 11 |
|
The development of multiple drug use among anabolic-androgenic steroid users: six subjective case reports. | 2008 Nov 28 |
|
[Conversion of 17 alpha-methyltestosterone to methandrostenolone by the bacterium Pimelobacter simplex VKPM Ac-1632 with the presence of cyclodextrins]. | 2008 Nov-Dec |
|
Oxandrolone Improves Height Velocity and BMI in Patients with Cystic Fibrosis. | 2009 |
|
A new mixed micellar electrokinetic chromatography method for analysis of natural and synthetic anabolic steroids. | 2009 Jan 15 |
|
Steroid metabolism in chimeric mice with humanized liver. | 2009 Nov |
|
Feasibility of capillary liquid chromatography/microchip atmospheric pressure photoionization mass spectrometry in analyzing anabolic steroids in urine samples. | 2010 Apr 15 |
|
CYP21-catalyzed production of the long-term urinary metandienone metabolite 17beta-hydroxymethyl-17 alpha-methyl-18-norandrosta-1,4,13-trien-3-one: a contribution to the fight against doping. | 2010 Jan |
|
Chronic anabolic androgenic steroid exposure alters corticotropin releasing factor expression and anxiety-like behaviors in the female mouse. | 2010 Nov |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23675320
Cell death was evaluated by staining PC12 cells treated for 48 h with 75 uM methandienone. Methandienone is toxic to neurons, inducing death in treated cells.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QA14AA03
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
||
|
DEA NO. |
4000
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
||
|
WHO-ATC |
A14AA03
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
||
|
WHO-ATC |
D11AE01
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
||
|
LIVERTOX |
613
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
||
|
WIKIPEDIA |
Designer-drugs-Methandrostenolone
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
||
|
NCI_THESAURUS |
C2360
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
||
|
WHO-VATC |
QD11AE01
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1734
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
72-63-9
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
3360
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
CHEMBL1418176
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
COZ1R7EOCC
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
METHANDROSTENOLONE
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
D008696
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
100000089098
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
983
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
m7293
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB13586
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
C87589
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
DTXSID2023276
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
SUB08812MIG
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
6300
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
42722
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | |||
|
6818
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY | RxNorm | ||
|
200-787-2
Created by
admin on Fri Dec 15 14:58:19 GMT 2023 , Edited by admin on Fri Dec 15 14:58:19 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)